The increased migratory and invasive ability of Bmi-1-overexpressing glioma cells were dramatically reversed by treatment with JSH-23, a specific NF-kappaB inhibitor that reduces the transcriptional activity of NF-kappaB, and these effects were accompanied by a reduction in MMP-9 expression (Figure 6A-D). The gene discussed is BMI1; the disease is central nervous system cancer.